Federal Register / Vol. 63, No. 134 /Tuesday, July 14, 1998 / Notices 37883

the offices of the Board of Governors.

Interested persons may express their

views in writing to the Reserve Bank

indicated for that notice or to the offices

of the Board of Governors. Comments

must be received not later than July 29,

1998.

A. Federal Reserve Bank of Chicago

(Philip Jackson, Applications Officer)

230 South LaSalle Street, Chicago,

Illinois 60690-1413:

1. Patricia Lee Joseph, Munster,

Indiana; to acquire additional voting

shares of First Bancshares, Inc.,

Highland, Indiana, and thereby

indirectly acquire Centier Bank,

Whiting, Indiana.

B. Federal Reserve Bank of St. Louis

(Randall C. Sumner, Vice President) 411

Locust Street, St. Louis, Missouri 63102-

2034:

1. David Lawrence Blaine, Paducah,

Kentucky; to acquire additional voting

shares of Ballard Kevil Bancorp, Inc.,

Kevil, Kentucky, and thereby indirectly

acquire The Kevil Bank, Kevil,

Kentucky.

C. Federal Reserve Bank of Kansas

City (D. Michael Manies, Assistant Vice

President) 925 Grand Avenue, Kansas

City, Missouri 64198-0001:

1. Ronald F. Tanner, Cornville,

Arizona, and Rex K. Alexander, Tulsa,

Oklahoma; to acquire voting shares of

BOC Banshares, Inc., Chouteau,

Oklahoma, and thereby indirectly

acquire voting shares of Bank of

Commerce, Chouteau, Oklahoma.

Board of Governors of the Federal Reserve

System, July 9, 1998.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 98–18743 Filed 7–13–98; 8:45 am]

BILLING CODE 6210–01–F

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and

Mergers of Bank Holding Companies

The companies listed in this notice

have applied to the Board for approval,

pursuant to the Bank Holding Company

Act of 1956 (12 U.S.C. 1841 et seq.)

(BHC Act), Regulation Y (12 CFR Part

225), and all other applicable statutes

and regulations to become a bank

holding company and/or to acquire the

assets or the ownership of, control of, or

the power to vote shares of a bank or

bank holding company and all of the

banks and nonbanking companies

owned by the bank holding company,

including the companies listed below.

The applications listed below, as well

as other related filings required by the

Board, are available for immediate

inspection at the Federal Reserve Bank

indicated. The application also will be

available for inspection at the offices of

the Board of Governors. Interested

persons may express their views in

writing on the standards enumerated in

the BHC Act (12 U.S.C. 1842(c)). If the

proposal also involves the acquisition of

a nonbanking company, the review also

includes whether the acquisition of the

nonbanking company complies with the

standards in section 4 of the BHC Act.

Unless otherwise noted, nonbanking

activities will be conducted throughout

the United States.

Unless otherwise noted, comments

regarding each of these applications

must be received at the Reserve Bank

indicated or the offices of the Board of

Governors not later than August 7, 1998.

A. Federal Reserve Bank of St. Louis

(Randall C. Sumner, Vice President) 411

Locust Street, St. Louis, Missouri 63102-

2034:

1. Bodcaw Bancshares, Inc., Stamps,

Arkansas; to become a bank holding

company by acquiring 100 percent of

the voting shares of Bodcaw Bank,

Stamps, Arkansas.

2. Arvest Bank Group, Inc.,

Bentonville, Arkansas; to merge with

Ameribank Corporation, Shawnee,

Oklahoma, and thereby indirectly

acquire United Oklahoma Bankshares,

Inc., Del City, Oklahoma; American

National Bank & Trust Company of

Shawnee, Shawnee, Oklahoma; and

United Bank, Del City, Oklahoma.

B. Federal Reserve Bank of Dallas

(W. Arthur Tribble, President) 2200

North Pearl Street, Dallas, Texas 75201-

2272:

1. First National Bank Group, Inc.,

Edinburg, Texas; to acquire 51 percent

of the voting shares of Nueces National

Bank, Corpus Christi, Texas.

Board of Governors of the Federal Reserve

System, July 9, 1998.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 98–18742 Filed 7–13–98; 8:45 am]

BILLING CODE 6210–01–F

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in

Permissible Nonbanking Activities or

to Acquire Companies that are

Engaged in Permissible Nonbanking

Activities

The companies listed in this notice

have given notice under section 4 of the

Bank Holding Company Act (12 U.S.C.

1843) (BHC Act) and Regulation Y, (12

CFR Part 225) to engage de novo, or to

acquire or control voting securities or

assets of a company, including the

companies listed below, that engages

either directly or through a subsidiary or

other company, in a nonbanking activity

that is listed in § 225.28 of Regulation

Y (12 CFR 225.28) or that the Board has

determined by Order to be closely

related to banking and permissible for

bank holding companies. Unless

otherwise noted, these activities will be

conducted throughout the United States.

Each notice is available for inspection

at the Federal Reserve Bank indicated.

The notice also will be available for

inspection at the offices of the Board of

Governors. Interested persons may

express their views in writing on the

question whether the proposal complies

with the standards of section 4 of the

BHC Act.

Unless otherwise noted, comments

regarding the applications must be

received at the Reserve Bank indicated

or the offices of the Board of Governors

not later than July 29, 1998.

A. Federal Reserve Bank of New

York (Betsy Buttrill White, Senior Vice

President) 33 Liberty Street, New York,

New York 10045-0001:

1. U.S.B Holding Co., Inc.,

Orangeburg, New York; to acquire

Tappen Zee Financial, Inc., Tarrytown,

New York, and thereby indirectly

acquire Tarrytowns Bank, FSB,

Tarrytown, New York, and theregy

engage in operating a savings

association, pursuant to §

225.28(b)(4)(ii) of Regulation Y.

Board of Governors of the Federal Reserve

System, July 9, 1998.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 98–18744 Filed 7–13–98; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Translation Advisory Committee for

Diabetes Prevention and Control

Programs: Notice of Charter Renewal

This gives notice under the Federal

Advisory Committee Act (Public Law

92–463) of October 6, 1972, that the

Translation Advisory Committee for

Diabetes Prevention and Control

Programs (TACDPCP) of the Centers for

Disease Control and Prevention (CDC),

Department of Health and Human

Services, has been renewed for a 2-year

period. The charter will now expire

June 15, 2000.

FOR FURTHER INFORMATION CONTACT:

Frank Vinicor, M.D., Executive

Secretary, TACDPCP, CDC, 4770 Buford
37884 Federal Register / Vol. 63, No. 134 /Tuesday, July 14, 1998 / Notices

Highway, NE, (M/S K–10), telephone

770–488–5000 or fax 770/488–5966.

Dated: July 7, 1998.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 98–18668 Filed 7–13–98; 8:45 am]

BILLING CODE 4861–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Hanford Thyroid Morbidity Study

Advisory Committee: Notice of Charter

Renewal

This gives notice under the Federal

Advisory Committee Act (Public Law

92–463) of October 6, 1972, that the

Hanford Thyroid Morbidity Study

Advisory Committee (HTMSAC) of the

Centers for Disease Control and

Prevention (CDC), Department of Health

and Human Services, has been renewed

for a 2-year period. The charter will now

expire June 13, 2000.

FOR FURTHER INFORMATION CONTACT:

Henry Falk, M.D., Executive Secretary,

HTMSAC, CDC, 4770 Buford Highway,

NE, (M/S F–28), telephone 770–488–

7300 or fax 770/488–7044.

Dated: July 7, 1998.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 98–18669 Filed 7–13–98; 8:45 am]

BILLING CODE 4861–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Announcement Number 99012]

Notice of Availability of Funds; Applied

Research Program in Emerging

Infections Novel Diagnostic Tests for

Infections of Public Health

Significance

Introduction

The Centers for Disease Control and

Prevention (CDC) announces the

availability of fiscal year (FY) 1999

funds for competitive grants and/or

cooperative agreements to support

applied research on emerging infections.

This announcement addresses the

development of novel diagnostic tests

for infections of public health

significance.

CDC is committed to achieving the

health promotion and disease

prevention objectives of Healthy People

2000, a national activity to reduce

morbidity and mortality and improve

the quality of life. This announcement

is related to the priority area of

Immunization and Infectious Diseases.

(For ordering a copy of Healthy People

2000, see the section WHERE TO OBTAIN

ADDITIONAL INFORMATION.)

Authority

This program is authorized under

Sections 301(a) and 317(k)(2) of the

Public Health Service Act, as amended

[42 U.S.C. 241(a) and 247b(k)(2)].

Smoke-Free Workplace

CDC strongly encourages all grant

recipients to provide a smoke-free

workplace and to promote the non-use

of all tobacco products, and Pub. L.

103–227, the Pro-Children’s Act of 1994,

prohibits smoking in certain facilities

that receive Federal funds in which

education, library, day-care, health-care

and early childhood development

services are provided to children.

Eligible Applicants

Applications may be submitted by

public and private nonprofit

organizations and governments and

their agencies. Thus, universities,

colleges, research institutions, hospitals,

other public and private organizations,

including State and local governments

or their bona fide agents, federally

recognized Indian tribal governments,

Indian tribes or Indian tribal

organizations.

Only one application will be accepted

from any single applicant, organization,

government, or agency in each focus

area.

Availability of Funds

Approximately $500,000 is available

in FY 1999 to fund two to three awards,

ranging from $160,000 to $250,000. It is

expected the awards will begin on or

about February 1, 1999, and will be

made for a 12-month budget period

within a project period of up to three

years. (The funding amounts listed

above are for the first 12-month budget

period and include both direct and

indirect costs.) The funding estimate is

subject to change.

Continuation awards within an

approved project period will be made

on the basis of satisfactory progress and

availability of funds.

Specifically, applications are solicited

for projects addressing any of the

following three areas:

1. Diagnostic Tests of High Sensitivity

and Specificity for Use in Clinical

Settings

The objective is to encourage the

development of highly sensitive and

specific diagnostic tests for infectious

disease agents of high public health

significance for which such tests are not

currently available.

2. Development and Evaluation of

Improved Tests for Malaria Diagnosis in

the U.S.

The objective is to develop and

evaluate a malaria diagnostic test that

does not require microscopic

examination of blood smears and: (a) is

at least as sensitive as microscopy (4

parasites per ul. of blood); (b) can detect

all 4 known species of human malaria

parasites; (c) has a specificity of at least

95 percent; (d) is simple to perform; and

(e) can provide results in less than 1

hour.

3. Diagnostic Tests for Field Use

The objective is to encourage the

development of field tests for infectious

disease agents of high public health

significance. Attributes sought in these

field tests are: low cost; use with

noninvasive or easy to collect

specimens; short time-to-result; stable

reagents; minimum risks to technicians;

sensitivity and specificity appropriate

for setting.

Applicants may submit separate

applications for projects in one or more

of the three focus areas. (See

Application Process Section,

Application Content area, for detailed

instructions.)

Determination of Which Instrument to

Use

Applicants must specify the type of

award for which they are applying,

either grant or cooperative agreement.

CDC will review the applications in

accordance with the evaluation criteria.

Before issuing awards, CDC will

determine whether a grant or

cooperative agreement is the

appropriate instrument based upon the

need for substantial CDC involvement in

the project. To assist applicants in

making a determination as to which

type of award to apply for, the following

information is provided:

1. Research Project Grants

A research project grant is one in

which substantial programmatic

involvement by CDC is not anticipated

by the recipient during the project

period. Applicants for grants must

demonstrate an ability to conduct the

proposed research with minimal

assistance, other than financial support,